General Updates

Jagsonpal Pharmaceuticals Ltd ( ::.:&.mu • -~ Sakht Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India) Ph.: +91124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com A CSR Initiative lJAGSONPAL! CIN. : L74899DL1978PLC009181 June 29, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Jagsonpal Pharmaceuticals to acquire 85% stake in Aequitas Healthcare Private Limited Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition Dear Sir/ Madam, We wish to inform you that the Company has entered into a Share Purchase Agreement (SPA) to acquire 85% of the paid up equity share capital of Aequitas Healthcare Private Limited (CIN:U36994MH2017PTC299446) (Target Company), which is engaged in the sale and distribution of pharmaceutical products to hospitals. The proposed acquisition is subject to fulfilment of the conditions in the SPA. The detailed disclosure as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/l/3762/2026 updated as on January 30, 2026 are enclosed herewith as Annexure-A. A press release being issued by the Company in this regard is attached as Annexure -B. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance office Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India) Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070 Jagsonpal Pharmaceuticals Ltd ( ::.:&.mu • -~ Sakht Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India) Ph.: +91124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com A CSR Initiative lJAGSONPAL! CIN. : L74899DL1978PLC009181 Annexure-A Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule Ill of the Listing Regulations read with SEBI master circular HO/49/14/14(7)2025-CFD- POD2/l/3762/2026 updaed as on January 30, 2026: Sr. Particulars Information a) Name of the target entity, details in brief Aequitas Healthcare Private Limited, a company such as size, turnover etc. incorporated in India under the provisions of the Companies Act, 2013, having its registered address at 305, Plot 119/120, Jaisingh Business Centre, 3rd Floor, Sahar Road, Andheri East, Mumbai, Maharashtra, India- 400099 and bearing CIN: U36994MH2017PTC299446. The revenue from operations for FY 2025-26 was INR 53.31 crores. b) Whether the acquisition would fall within The acquisition does not fall within related party related party transaction(s) and whether transactions. The promoter/promoter group of the the promoter/ promoter group/ group Company have no interest in Aequitas Healthcare Private companies have any interest in the entity Limited. being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” c) Industry to which the entity being acquired Pharmaceuticals and Healthcare belongs d) Objects and effects of acquisition This acquisition aligns with the Company's strategic (including but not limited to, disclosure of objective of gaining access to the hospital channel and reasons for acquisition of target entity, if institutional doctor network for the Company’s products, its business is outside the main line of significantly reducing the time required to build these business of the listed entity) relationships organically. e) Brief details of any governmental or No governmental or regulatory approvals are required for regulatory approvals required for the the proposed acquisition. acquisition f) Indicative time period for completion of Expected to be completed by 15th July 2026 the acquisition g) Nature of consideration - whether cash Cash Consideration consideration or share swap and details of the same h) Cost of acquisition or the price at which Cash consideration aggregating INR- 20.8 Crore for 85% the shares are acquired stake i) Percentage of shareholding/ control Company will initially acquire 85% of the paid up equity acquired and/ or number of shares acquired share capital of the Target Company. Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India) Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070 Jagsonpal Pharmaceuticals Ltd ( ::.:&.mu • -~ Sakht Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India) Ph.: +91124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com A CSR Initiative lJAGSONPAL! CIN. : L74899DL1978PLC009181 j) Brief background about the entity acquired Aequitas Healthcare Private Limited is a 8-year-old in terms of products/line of business pharmaceutical company headquartered in Mumbai, acquired, date of incorporation, history of operating pre-dominantly in sales of pharmaceutical last 3 years turnover, country in which the products to hospitals. acquired entity has presence and any other significant information (in brief) Aequitas was incorporated on 07/09/2017. The revenue from operations for previous three years is as follows, FY Turnover (in INR Crores) 2025-26 53.31 2024-25 56.19 2023-24 53.71 Countries in which Aequitas has presence: India Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India) Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070 Annexure-B h&.111u • 'C5akhl !JAGSONPAL! Jagsonpal Pharmaceuticals to acquire 85% stake in Aequitas Healthcare Transaction marks its strategic entry in the Hospital segment Gurugram, India | June 29, 2026 – Jagsonpal Pharmaceuticals Ltd. (Jagsonpal) today announced that it has entered into a definitive Agreement for the acquisition of 85% equity stake in Aequitas Healthcare Private Limited ("Aequitas"), a Mumbai-based pharmaceutical company primarily focused on sale and distribution of pharmaceutical products to hospitals. The proposed acquisition marks Jagsonpal's strategic entry into the hospital segment and is aligned with the Company's long-term vision of strengthening its presence in India’s growing healthcare ecosystem. Founded in 2017, Aequitas has a robust business covering all leading hospital chains in India. The company had revenues of Rs. 53 crores in FY26 The total consideration for 85% stake would be Rs. 20.8 crores, which shall be funded from internal accruals of Jagsonpal. The current Directors of Aequitas shall retain 15% stake and shall continue to be associated with the business. Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal stated: "The proposed acquisition of Aequitas represents an important strategic milestone for Jagsonpal. It provides us with a ready platform for a meaningful presence in the hospital segment, which now contributes ~10% of pharma industry sales and growing faster. We strongly believe that Jagsonpal's portfolio of established brands will greatly benefit from Aequitas' strong institutional relationships, delivering sustainable long-term value to our shareholders." Mr. Amrut Medhekar, Chief Operating Officer, Jagsonpal stated: “This transaction is a structurally transformative pivot that moves Jagsonpal from a legacy retail prescription player to Omnichannel Specialty healthcare business in India and is reflective of our long-term commitment to building scalable, high-quality healthcare [Showing first 8,000 characters — download PDF for full document]